image
Healthcare - Biotechnology - NASDAQ - US
$ 1.66
-1.78 %
$ 83.2 M
Market Cap
-0.55
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HLVX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.66 USD, HilleVax, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HLVX stock under the base case scenario is HIDDEN Compared to the current market price of 1.66 USD, HilleVax, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HLVX stock under the best case scenario is HIDDEN Compared to the current market price of 1.66 USD, HilleVax, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HLVX

image
$2.2$2.2$2.1$2.1$2.0$2.0$1.9$1.9$1.8$1.8$1.7$1.7$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-155 M OPERATING INCOME
-16.46%
-147 M NET INCOME
-19.18%
-109 M OPERATING CASH FLOW
-25.36%
58.4 M INVESTING CASH FLOW
161.71%
-11.8 M FINANCING CASH FLOW
-9.96%
0 REVENUE
0.00%
-36.2 M OPERATING INCOME
-37.04%
-33.9 M NET INCOME
-31.46%
-18.2 M OPERATING CASH FLOW
34.63%
68.9 M INVESTING CASH FLOW
36.04%
0 FINANCING CASH FLOW
100.00%
Balance Sheet HilleVax, Inc.
image
Current Assets 178 M
Cash & Short-Term Investments 171 M
Receivables 0
Other Current Assets 6.92 M
Non-Current Assets 14.3 M
Long-Term Investments 0
PP&E 12.7 M
Other Non-Current Assets 1.65 M
88.97 %3.59 %6.59 %Total Assets$192.7m
Current Liabilities 16.5 M
Accounts Payable 3.24 M
Short-Term Debt 3.57 M
Other Current Liabilities 9.65 M
Non-Current Liabilities 21.7 M
Long-Term Debt 20.9 M
Other Non-Current Liabilities 806 K
8.47 %9.34 %25.25 %54.82 %Total Liabilities$38.2m
EFFICIENCY
Earnings Waterfall HilleVax, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 155 M
Operating Income -155 M
Other Expenses -8.02 M
Net Income -147 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)000(155m)(155m)8m(147m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-95.33% ROE
-95.33%
-76.43% ROA
-76.43%
-86.37% ROIC
-86.37%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis HilleVax, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)202020202021202120222022202320232024202420252025
Net Income -147 M
Depreciation & Amortization 3.2 M
Capital Expenditures -522 K
Stock-Based Compensation 20.8 M
Change in Working Capital -14.6 M
Others 27.8 M
Free Cash Flow -109 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets HilleVax, Inc.
image
HLVX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership HilleVax, Inc.
image
Sold
0-3 MONTHS
63.8 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
363 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Frazier Life Sciences Appoints Aditya Kohli to Partner PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ: HLVX, IPO in 2022), Phathom Pharmaceuticals (NASDAQ: PHAT, IPO in 2019), and Scout Bio (acquired by Ceva Santé Animale). He previously acted. businesswire.com - 2 weeks ago
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 million and $303.5 million, respectively. globenewswire.com - 1 month ago
What Makes HilleVax (HLVX) a New Buy Stock HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 6 months ago
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX) NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. accesswire.com - 8 months ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX) NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. accesswire.com - 8 months ago
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. accesswire.com - 8 months ago
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. accesswire.com - 8 months ago
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. accesswire.com - 8 months ago
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. accesswire.com - 8 months ago
HLVX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your HilleVax, Inc. investment NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. accesswire.com - 8 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ:HLVX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 8 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 8 months ago
8. Profile Summary

HilleVax, Inc. HLVX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 83.2 M
Dividend Yield 0.00%
Description HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Contact 75 State Street, Boston, MA, 02109 https://www.hillevax.com
IPO Date April 29, 2022
Employees 14
Officers Dr. Robert M. Hershberg M.D., Ph.D. Co-Founder, President, Chief Executive Officer & Chairman of the Board Dr. Aditya Kohli Ph.D. Co-Founder & Director Mr. Paul S. Bavier J.D. General Counsel, Secretary & Chief Administrative Officer Mr. Shane A. Maltbie Chief Financial Officer & Treasurer Dr. Anju Chatterji Ph.D. Chief Technology Officer